vs
Side-by-side financial comparison of KEMPER Corp (KMPR) and Insulet Corporation (PODD). Click either name above to swap in a different company.
KEMPER Corp is the larger business by last-quarter revenue ($1.1B vs $783.7M, roughly 1.4× Insulet Corporation). Insulet Corporation runs the higher net margin — 13.0% vs -0.7%, a 13.7% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs -4.7%). KEMPER Corp produced more free cash flow last quarter ($166.2M vs $48.2M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs -0.5%).
Kemper Corporation is an American insurance provider with corporate headquarters located in Chicago, Illinois. With nearly $13 billion in assets, the Kemper family of companies provides insurance to individuals, families, and businesses.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
KMPR vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $783.7M |
| Net Profit | $-8.0M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | -0.7% | 13.0% |
| Revenue YoY | -4.7% | 31.2% |
| Net Profit YoY | -108.2% | 0.9% |
| EPS (diluted) | $-0.03 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $783.7M | ||
| Q3 25 | $1.2B | $706.3M | ||
| Q2 25 | $1.2B | $649.1M | ||
| Q1 25 | $1.2B | $569.0M | ||
| Q4 24 | $1.2B | $597.5M | ||
| Q3 24 | $1.2B | $543.9M | ||
| Q2 24 | $1.1B | $488.5M | ||
| Q1 24 | $1.1B | $441.7M |
| Q4 25 | $-8.0M | $101.6M | ||
| Q3 25 | $-21.0M | $87.6M | ||
| Q2 25 | $72.6M | $22.5M | ||
| Q1 25 | $99.7M | $35.4M | ||
| Q4 24 | $97.4M | $100.7M | ||
| Q3 24 | $73.7M | $77.5M | ||
| Q2 24 | $75.4M | $188.6M | ||
| Q1 24 | $71.3M | $51.5M |
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | — | 69.5% |
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | 11.2% | 16.2% | ||
| Q2 24 | 10.1% | 11.2% | ||
| Q1 24 | 7.6% | 12.9% |
| Q4 25 | -0.7% | 13.0% | ||
| Q3 25 | -1.7% | 12.4% | ||
| Q2 25 | 5.9% | 3.5% | ||
| Q1 25 | 8.4% | 6.2% | ||
| Q4 24 | 8.2% | 16.9% | ||
| Q3 24 | 6.3% | 14.2% | ||
| Q2 24 | 6.7% | 38.6% | ||
| Q1 24 | 6.2% | 11.7% |
| Q4 25 | $-0.03 | $1.42 | ||
| Q3 25 | $-0.34 | $1.24 | ||
| Q2 25 | $1.12 | $0.32 | ||
| Q1 25 | $1.54 | $0.50 | ||
| Q4 24 | $1.51 | $1.38 | ||
| Q3 24 | $1.14 | $1.08 | ||
| Q2 24 | $1.16 | $2.59 | ||
| Q1 24 | $1.10 | $0.73 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $943.5M | $930.8M |
| Stockholders' EquityBook value | $2.7B | $1.5B |
| Total Assets | $12.5B | $3.2B |
| Debt / EquityLower = less leverage | 0.35× | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $371.2M | — | ||
| Q2 25 | $407.6M | — | ||
| Q1 25 | $545.3M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $696.9M | — | ||
| Q2 24 | $539.1M | — | ||
| Q1 24 | $520.7M | — |
| Q4 25 | $943.5M | $930.8M | ||
| Q3 25 | $943.1M | $934.9M | ||
| Q2 25 | $942.6M | $939.0M | ||
| Q1 25 | $942.1M | $1.6B | ||
| Q4 24 | $1.4B | $1.3B | ||
| Q3 24 | $1.4B | $1.4B | ||
| Q2 24 | $1.4B | $1.4B | ||
| Q1 24 | $1.4B | $1.4B |
| Q4 25 | $2.7B | $1.5B | ||
| Q3 25 | $2.7B | $1.4B | ||
| Q2 25 | $370.0M | $1.5B | ||
| Q1 25 | $366.0M | $1.3B | ||
| Q4 24 | $2.8B | $1.2B | ||
| Q3 24 | $2.8B | $1.1B | ||
| Q2 24 | $358.0M | $998.4M | ||
| Q1 24 | $2.6B | $790.7M |
| Q4 25 | $12.5B | $3.2B | ||
| Q3 25 | $12.4B | $3.0B | ||
| Q2 25 | $12.6B | $3.5B | ||
| Q1 25 | $12.5B | $3.5B | ||
| Q4 24 | $12.6B | $3.1B | ||
| Q3 24 | $12.6B | $3.0B | ||
| Q2 24 | $12.6B | $2.9B | ||
| Q1 24 | $12.6B | $2.6B |
| Q4 25 | 0.35× | 0.61× | ||
| Q3 25 | 0.35× | 0.68× | ||
| Q2 25 | 2.55× | 0.64× | ||
| Q1 25 | 2.57× | 1.21× | ||
| Q4 24 | 0.50× | 1.07× | ||
| Q3 24 | 0.50× | 1.21× | ||
| Q2 24 | 3.88× | 1.36× | ||
| Q1 24 | 0.54× | 1.72× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.0M | $183.3M |
| Free Cash FlowOCF − Capex | $166.2M | $48.2M |
| FCF MarginFCF / Revenue | 14.7% | 6.2% |
| Capex IntensityCapex / Revenue | 0.8% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | $553.9M | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.0M | $183.3M | ||
| Q3 25 | $139.9M | $125.7M | ||
| Q2 25 | $89.6M | $196.5M | ||
| Q1 25 | $180.0M | $63.8M | ||
| Q4 24 | $175.1M | $147.7M | ||
| Q3 24 | $141.9M | $98.5M | ||
| Q2 24 | $22.9M | $96.5M | ||
| Q1 24 | $43.0M | $87.6M |
| Q4 25 | $166.2M | $48.2M | ||
| Q3 25 | $133.4M | $100.1M | ||
| Q2 25 | $82.0M | $177.9M | ||
| Q1 25 | $172.3M | $51.5M | ||
| Q4 24 | $165.4M | $94.1M | ||
| Q3 24 | $131.4M | $71.8M | ||
| Q2 24 | $5.2M | $74.0M | ||
| Q1 24 | $27.7M | $65.5M |
| Q4 25 | 14.7% | 6.2% | ||
| Q3 25 | 10.8% | 14.2% | ||
| Q2 25 | 6.7% | 27.4% | ||
| Q1 25 | 14.4% | 9.1% | ||
| Q4 24 | 13.9% | 15.7% | ||
| Q3 24 | 11.1% | 13.2% | ||
| Q2 24 | 0.5% | 15.1% | ||
| Q1 24 | 2.4% | 14.8% |
| Q4 25 | 0.8% | 17.2% | ||
| Q3 25 | 0.5% | 3.6% | ||
| Q2 25 | 0.6% | 2.9% | ||
| Q1 25 | 0.6% | 2.2% | ||
| Q4 24 | 0.8% | 9.0% | ||
| Q3 24 | 0.9% | 4.9% | ||
| Q2 24 | 1.6% | 4.6% | ||
| Q1 24 | 1.3% | 5.0% |
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 1.23× | 8.73× | ||
| Q1 25 | 1.81× | 1.80× | ||
| Q4 24 | 1.80× | 1.47× | ||
| Q3 24 | 1.93× | 1.27× | ||
| Q2 24 | 0.30× | 0.51× | ||
| Q1 24 | 0.60× | 1.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
KMPR
| Specialty Property Casualty Insurance Segment | $995.1M | 88% |
| Life Insurance Segment1 | $140.7M | 12% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
